FIGURE 1 from Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC

Mari Nakazawa,Guilherme Harada,Paola Ghanem, Adrian Bubie,Lesli A. Kiedrowski,Joseph C. Murray,Kristen A. Marrone,Susan C. Scott,Stefanie Houseknecht,Christina J. Falcon, Patrick Evans, Josephine Feliciano,Christine L. Hann, David S. Ettinger,Kellie N. Smith,Valsamo Anagnostou,Patrick M. Forde,Julie R. Brahmer, Benjamin Levy,Alexander Drilon,Vincent K. Lam

crossref（2024）

引用 0|浏览7

暂无评分

摘要

A,EML4-ALK variant type observed in clinical and liquid biopsy cohorts. B, Clinically relevant somatic co-mutations observed in clinical and liquid biopsy (LB) cohorts. Copy-number deletion/loss not reported in the liquid biopsy cohort; loss-of-function mutations in CDKN2A/B, PTEN, and CTNNB1 are included.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要